Received Jul 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | — | — |
Dose 1: Oct2020, Dose 2: Apr2021; slurred speech and eye issues/eventually diagnosed as Multiple Sclerosis; This is a spontaneous report received from a Consumer or other non HCP. An adult female patient (not pregnant) received BNT162b2 (BNT162B2), in Apr2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. It was unknown if the patient has known allergies. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), administration date: Oct2020, for COVID-19 immunization. The following information was reported: MULTIPLE SCLEROSIS (disability, medically significant) with onset Apr2021, outcome "not recovered", described as "slurred speech and eye issues/eventually diagnosed as Multiple Sclerosis"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious), outcome "unknown", described as "Dose 1: Oct2020, Dose 2: Apr2021". It was unknown if therapeutic measures were taken as a result of multiple sclerosis. Clinical course: After the 2nd Covid shot, the patient began having a slurred speech and eye issues. This was eventually diagnosed as Multiple Sclerosis. The event Multiple Sclerosis resulted to disability or permanent damage. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.